Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma

Seminars in Hematology

Volumn 48, Issue 1, 2011, Pages 39-45

  Calvo, Katherine R ^a   Landgren, Ola ^b   Roccaro, Aldo M ^c   Ghobrial, Irene M ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA;

ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CLASSIFICATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HOMING; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; HUMAN; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RNA ISOLATION; RNA STABILITY;

CYTOGENETIC ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA;

EID: 78650984265     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.11.007     Document Type: Article

References (55)

1. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
2. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
3. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
4. Lim L.P., Lau N.C., Garrett-Engele P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
5. Miranda K.C., Huynh T., Tay Y., et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
6. Calin G.A., Cimmino A., Fabbri M., et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008, 105:5166-5171.
7. Hwang H.W., Wentzel E.A., Mendell J.T. A hexanucleotide element directs microRNA nuclear import. Science 2007, 315:97-100.
8. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36:D154-D158.
9. Jima D.D., Zhang J., Jacobs C., et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010 Aug 23, Epub ahead of print.
10. Baskerville S., Bartel D.P. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005, 11:241-247.
11. Li S.C., Tang P., Lin W.C. Intronic microRNA: discovery and biological implications. DNA Cell Biol 2007, 26:195-207.
12. Xiao C., Srinivasan L., Calado D.P., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
13. Ventura A., Young A.G., Winslow M.M., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
14. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
15. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
16. Zhang J., Jima D.D., Jacobs C., et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113:4586-4594.
17. Zhou Y., Chen L., Barlogie B., et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A 2010, 107:7904-7909.
18. Pichiorri F., Suh S.S., Ladetto M., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008, 105:12885-12890.
19. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
20. Martins G., Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008, 26:133-169.
21. Novotny G.W., Sonne S.B., Nielsen J.E., et al. Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death Differ 2007, 14:879-882.
22. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
23. Petrocca F., Visone R., Onelli M.R., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
24. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
25. Loffler D., Brocke-Heidrich K., Pfeifer G., et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110:1330-1333.
26. Wang K., Li P.F. Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem 2010, 285:16958-16966.
27. Todoerti K., Barbui V., Pedrini O., et al. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 2010, 95:260-269.
28. Roccaro A.M., Sacco A., Thompson B., et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113:6669-6680.
29. Lerner M., Harada M., Loven J., et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009, 315:2941-2952.
30. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
31. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944-13949.
32. Corthals S.L., Jongen-Lavrencic M., de Knegt Y., et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010, 34:677-681.
33. Unno K., Zhou Y., Zimmerman T., Platanias L.C., Wickrema A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009, 50:1865-1871.
34. Ronchetti D., Lionetti M., Mosca L., et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics 2008, 1:37.
35. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
36. Shaughnessy J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
37. Chen Y.H., Lavelle D., DeSimone J., Uddin S., Platanias L.C., Hankewych M. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Blood 1999, 94:251-259.
38. Lavelle D., Chen Y.H., Hankewych M., DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001, 68:170-178.
39. Stewart J.P., Thompson A., Santra M., Barlogie B., Lappin T.R., Shaughnessy J. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 2004, 126:72-76.
40. Lionetti M., Biasiolo M., Agnelli L., et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114:e20-e26.
41. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
42. Jenner M.W., Leone P.E., Walker B.A., et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007, 110:3291-3300.
43. Eis P.S., Tam W., Sun L., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005, 102:3627-3632.
44. Kluiver J., Poppema S., de Jong D., et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005, 207:243-249.
45. Roccaro A.M., Sacco A., Chen C., et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009, 113:4391-4402.
46. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
47. Lotterman C.D., Kent O.A., Mendell J.T. Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle 2008, 7:2493-2499.
48. Visone R., Croce C.M. MiRNAs and cancer. Am J Pathol 2009, 174:1131-1138.
49. Johnson S.M., Grosshans H., Shingara J., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
50. Medina P.P., Slack F.J. microRNAs and cancer: an overview. Cell Cycle 2008, 7:2485-2492.
51. Gutierrez N.C., Sarasquete M.E., Misiewicz-Krzeminska I., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637.
52. Li J., Smyth P., Flavin R., et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007, 7:36.
53. Doleshal M., Magotra A.A., Choudhury B., Cannon B.D., Labourier E., Szafranska A.E. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008, 10:203-211.
54. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
55. Visone R., Rassenti L.Z., Veronese A., et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009, 114:3872-3879.